Live Breaking News & Updates on Capitello 291

Stay updated with breaking news from Capitello 291. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Capivasertib and Fulvestrant for Patients with Aromatase Inhibitor-resistant Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer: Results from the Phase III CAPItello-291 Trial

Hope Rugo, MD reviews key data from the CAPItello-291 phase 3 trial recently presented at the San Antonio Breast Cancer Symposium in December 2022. ....

Aromatase Inhibitor Resistant Hormone , Human Epidermal Growth Factor Receptor , Advanced Breast Cancer , Breast Cancer , Hr Breast Cancer , Her2 Breast Cancer , Capitello Trial , Capitello 291 , Jcdk4 6 Inhibitor , Pik3ca Alteration , Akt1 Alteration , Pten Alteration , Capivasertib Adverse Events , Adverse Events , Fulvestrant Capivasertib , Fulvestrant Adverse Events , Aromatase Inhibitor , Aromatase Inhibitor Resistant ,

HR+/HER2- Breast Cancer: Inhibiting the PI3K/AKT/mTOR Pathway

Dr Vidal expands on use of PI3K/AKT/mTOR pathway inhibitors following frontline progression, focusing on the PI3K inhibitor alpelisib for patients with PIK3CA mutations, as well as capivasertib, an AKT inhibitor in development. ....

Aditya Bardia , Gregory Vidal , Komal Jhaveri , Hr Her2 Breast Cancer , Cdk4 6 Inhibitors , Second Line Therapies , Endocrine Therapy , Endocrine Resistance , Akt Inhibitors , Capitello 291 , Maintain Trial , Ember 3 , Oral Serds , Viktoria 1 ,